Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (15,612,000)	$ (16,134,000)
Adjustments to reconcile net loss to cash used in operating activities:
Change in fair value of common stock warrant and option liabilities	(3,209,000)	(8,946,000)
Change in fair value of contingent consideration	(70,000)	(210,000)
Issuance and offering costs	314,000	769,000
Depreciation	439,000	929,000
Amortization of intangible assets	40,000	116,000
Lease amortization	884,000	1,276,000
Impairment of intangible assets	404,000	3,302,000
Impairment of goodwill	0	1,648,000
(Gain) Loss on disposal of equipment	(314,000)	23,000
Loss on disposal of intangible assets	0	222,000
Stock-based compensation	1,106,000	1,541,000
Bad debt expense	60,000	76,000
Gain on sale of Verdeca	(1,138,000)	0
Realized gain on corporate securities	0	(10,221,000)
Write-down of inventories	2,471,000	3,593,000
Gain on extinguishment of PPP loan	0	(1,123,000)
Impairment of property and equipment	530,000	1,534,000
Changes in operating assets and liabilities:
Accounts receivable and other receivables	592,000	(40,000)
Inventories	1,118,000	(2,383,000)
Prepaid expenses and other current assets	91,000	56,000
Other noncurrent assets	16,000	(158,000)
Accounts payable and accrued expenses	(757,000)	(372,000)
Amounts due to related parties	(16,000)	(16,000)
Unearned revenue	0	(8,000)
Other current liabilities	6,000	1,000
Operating lease payments	(932,000)	(1,343,000)
Net cash used in operating activities	(13,977,000)	(25,868,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment	920,000	19,000
Proceeds from sale of Verdeca - earn-out received	569,000
Purchases of property and equipment	(72,000)	(1,007,000)
Acquisitions, net of cash acquired	0	(4,250,000)
Proceeds from sales and maturities of investments	0	21,846,000
Net cash provided by investing activities	1,417,000	16,608,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on notes payable	0	(2,146,000)
Proceeds from exercise of warrants	0	22,000
Proceeds from exercise of stock options and purchases through ESPP	7,000	39,000
Capital contributions received from non-controlling interest	0	750,000
Net cash provided by financing activities	4,519,000	21,900,000
Effects of foreign currency translation on cash and cash equivalents	0	2,000
Net increase (decrease) in cash, cash equivalents and restricted cash	(8,041,000)	12,642,000
Cash, cash equivalents and restricted cash — beginning of period	28,685,000	16,043,000
Cash, cash equivalents and restricted cash — end of period	20,644,000	28,685,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	1,000	25,000
Cash paid for taxes	0	1,000
NONCASH TRANSACTIONS:
Fair value of shares of common stock issued at closing of Arcadia Wellness transaction	0	2,053,000
Right of use assets obtained in exchange for new operating lease liabilities	114,000	1,664,000
Proceeds From Sale Of Property And Equipment In Accounts Receivable And Other Receivables	19,000	0
Proceeds from sale of Verdeca in accounts receivable and other receivables	569,000	0
Accounting Standards Update 2020-06 [Member]
NONCASH TRANSACTIONS:
Common stock warrant liabilities reclassified to equity	3,392,000	0
August 2022 Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, pre-funded warrants and preferred investment options	5,000,000	0
Payments of offering costs	(488,000)	0
January 2021 PIPE Purchase Agreement [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants from offering	0	25,147,000
Payments of offering costs	0	(1,912,000)
NONCASH TRANSACTIONS:
Common stock warrants issued to placement agent and included in offering costs related to purchase agreement	0	942,000
August 2022 RDO Securities Purchase Agreement [Member]
NONCASH TRANSACTIONS:
Common stock options issued to placement agent and included in offering costs	$ 191,000	$ 0